Jefferies Group Research Analysts Lower Earnings Estimates for Merck & Company, Inc. (MRK)
Merck & Company, Inc. (NYSE:MRK) – Equities research analysts at Jefferies Group lowered their FY2018 EPS estimates for shares of Merck & in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $4.16 per share for the year, down from their prior estimate of $4.18. Jefferies Group has a “Underperform” rating on the stock. Jefferies Group also issued estimates for Merck &’s FY2019 earnings at $4.16 EPS, FY2020 earnings at $4.38 EPS and FY2021 earnings at $4.74 EPS.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 26.82% and a net margin of 11.60%. The company had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter last year, the company earned $1.07 EPS. The company’s quarterly revenue was down 2.0% on a year-over-year basis.
MRK has been the topic of several other research reports. BidaskClub downgraded Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. J P Morgan Chase & Co set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Sunday. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & in a research report on Wednesday. BMO Capital Markets set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Wednesday, October 18th. Finally, Zacks Investment Research downgraded Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $67.07.
Institutional investors have recently added to or reduced their stakes in the stock. Stelac Advisory Services LLC purchased a new position in Merck & in the 2nd quarter valued at approximately $104,000. Perennial Advisors LLC grew its stake in Merck & by 10.7% in the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after buying an additional 157 shares in the last quarter. Cascade Investment Advisors Inc. grew its stake in Merck & by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after buying an additional 232 shares in the last quarter. Vigilant Capital Management LLC grew its stake in Merck & by 16.7% in the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares in the last quarter. Finally, Solaris Asset Management LLC grew its stake in Merck & by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after buying an additional 115 shares in the last quarter. Institutional investors and hedge funds own 72.86% of the company’s stock.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.